Skip to main content

Table 1 Patient characteristics before propensity score matching

From: Comparison of operative outcomes between monopolar and bipolar coagulation in hepatectomy: a propensity score-matched analysis in a single center

 

Monopolar (n = 160)

Bipolar (n = 104)

P value

Age

68 (17–87, 14)

69 (30–85, 13)

0.745

Sex (male/female)

116/44

73/31

0.685

BMI

22.7 (12.5–32.3, 4.50)

22.7 (15.9–37.1, 4.40)

1.000

ASA (1/2/3)

14/130/16

10/79/15

0.516

Diagnosis (HCC/CCC/meta/biliary tract cancer/benign disease/other)

72/10/42/16/17/3

65/6/21/3/9/0

0.045

Background liver disease (normal/HCV/HBV/ASH/NASH/other)

90/43/12/4/8/3

42/43/9/3/5/2

0.135

Liver fibrosisa (f0–1, f2–4)

57/56

33/51

0.120

Type of resection (partial/lateral/subsegmentectomy/segmentectomy/hemihepatectectomy/trisegmentectomy)

48/2/38/22/48/2

22/5/33/14/30/0

0.362

Number of resected lesions

1 (1–16, 0)

1 (1–3, 0)

0.970

Size of the largest nodule on preoperative imagingb (cm)

2.5 (0.60–20, 3.0)

2.5 (0.50–13, 2.0)

0.776

Number of nodules on preoperative imagingb

1 (1–10, 1)

1 (1–10, 1)

0.868

Lymph node dissection (yes/no)

37/123

11/93

0.010

Biliary reconstruction (yes/no)

24/136

7/97

0.041

Intraoperative drain insert (yes/no)

159/1

104/0

0.606

Duration of drain placement

5 (0–223, 5)

5 (2–94, 3)

0.272

Neoadjuvant chemotherapy (yes/no/previous)

27/120/13

11/90/3

0.059

Total bilirubin (mg/dL)

0.70 (0.3–3.1, 0.30)

0.80 (0.40–1.7, 0.40)

0.285

 ≥ 1.1/ < 1.1

29/131

19/85

0.976

Aspartate transaminase (IU/L)

28 (13–155, 18)

35 (9–104, 26)

0.021

 ≥ 31/ < 31

67/93

62/42

0.005

Albumin (g/dL)

4.1 (3.0–5.0, 0.40)

3.9 (2.3–4.9, 0.50)

0.001

 ≥ 3.9/ < 3.9

122/38

58/46

 < 0.001

Prothrombin activity (%)

100 ± 17

92 ± 15

 < 0.001

 ≥ 69/ < 69

154/6

100/4

0.605

Activated partial thromboplastin time (%)

91 (24–140, 30)

81 (46–140, 24)

0.003

 ≥ 69/ < 69

131/29

84/20

0.821

Hemoglobin (g/dL)

13 ± 2.2

13 ± 1.8

0.009

 ≥ 11.4/ < 11.4

136/24

75/29

0.011

Platelet (× 104/μL)

18.1 (3.20–61.8, 9.20)

16.4 (4.80–49.9, 8.60)

0.185

 ≥ 15.3/ < 15.3

102/58

65/39

0.837

Blood urea nitrogen (mg/dL)

14.9 (7.00–39.5, 5.60)

14.6 (7.00–27.2, 6.40)

0.423

 ≥ 20.0/ < 20.0

24/136

16/88

0.932

Creatinine (mg/dL)

0.78 (0.35–5.50, 0.30)

0.75 (0.43–2.30, 0.28)

0.427

 ≥ 1.07/ < 1.07

21/139

12/92

0.703

C-reactive proteinc (mg/dL)

0.10 (0.00–9.80, 0.18)

0.11 (0.01–24.2, 0.28)

0.439

 ≥ 0.14/ < 0.14

61/93

35/44

0.491

ICGR15d (%)

15 (1–51, 10)

11 (1–45, 10)

0.003

 ≥ 10/ < 10

116/37

54/45

0.002

Child–Pugh score

5 (5–6, 0)

5 (5–8, 0)

0.352

  1. Continuous data are presented as median (range, interquartile range) or mean ± standard deviation, whereas categorical data are shown as number of patients. Significant P values are in boldface
  2. BMI, body mass index; ASA, American Society of Anesthesiologists; HCC, hepatocellular carcinoma; CCC, cholangiocellular carcinoma; meta, liver metastasis; HCV, hepatitis C virus; HBV, hepatitis B virus; ASH, alcoholic steatohepatitis; NASH, non-alcoholic steatohepatitis; ICGR15, indocyanine green retention rate at 15 min
  3. aData on liver fibrosis were partially lacking (monopolar, 113 cases; bipolar, 84 cases)
  4. bData on the size of the largest nodule and number of nodules were partially lacking because biliary tract cancer and benign disease could not be accurately measured (monopolar, 133 cases; bipolar, 97 cases)
  5. cData on C-reactive protein were partially lacking (monopolar, 154 cases; bipolar, 79 cases)
  6. dData on ICGR15 were partially lacking (monopolar, 153 cases; bipolar, 99 cases)